Skip to content
Insider tapeFilings through Fri, Nov 20
My stocks

Vertex Pharmaceuticals (VRTX) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareVRTX

Closing price · Nov 20, 2026 $515.02 -1.1% on the day · +22.0% over 12 months 52-week range $422.32 – $558.88
Get VRTX alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling14last 12 months
Reported sales$140M98 of 98 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 1, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Nancy Thornberry, Director sold 1,000 shares at $547.86 ($548K).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All VRTX insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

VRTX insider transactions (Form 4)

Open-market purchases and sales. 98 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Nancy ThornberryDirector Sell Plan 1,0001,109 held (−47%) $547.86 $548K -6.0% —
Nov 18SEC Sangeeta N. BhatiaDirector Sell Plan 2714,653 held (−6%) $547.86 $148K -6.0% —
Nov 16SEC Charles F. Wagner Jr.Evp, Co & Fo Sell Plan 15,28631,764 held (−32%) $547.87 $8.4M -6.0% —
Nov 10SEC Reshma KewalramaniCEO, President Sell Plan 11,86686,471 held (−12%) $531.53 $6.3M -3.1% —
Jul 7SEC Duncan McKechnieEvp, Chief Commercial Officer Sell Plan 1,54111,001 held (−12%) $519.00 $800K -0.8% —
Jul 7SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 1,50045,321 held (−3%) $524.99 $787K -1.9% —
Jul 6SEC Joy LiuGeneral Counsel Sell Plan 82819,131 held (−4%) $502.71 $416K +2.4% —
Jun 30SEC Carmen BozicEvp And Cmo Sell Plan 59615,337 held (−4%) $482.50 $288K +6.7% —
Jun 23SEC Carmen BozicEvp And Cmo Sell Plan 1,02015,933 held (−6%) $462.17 $471K +11.4% —
Jun 17SEC Carmen BozicEvp And Cmo Sell Plan 4,06216,953 held (−19%) $450.00 $1.8M +14.4% —
Jun 9SEC Carmen BozicEvp And Cmo Sell Plan 1,74521,015 held (−8%) $450.00 $785K +14.4% —
Jun 3SEC Joy LiuGeneral Counsel Sell Plan 82819,959 held (−4%) $439.91 $364K +17.1% —
Jun 2SEC Carmen BozicEvp And Cmo Sell Plan 1,97422,760 held (−8%) $450.00 $888K +14.4% —
May 19SEC Carmen BozicEvp And Cmo Sell Plan 1,35424,734 held (−5%) $453.45 $614K +13.6% —
May 19SEC Mark E. BunnageEvp, Chief Scientific Officer Sell Plan 337,284 held (−0%) $453.45 $15K +13.6% —
May 14SEC Carmen BozicEvp And Cmo Sell Plan 6,98826,088 held (−21%) $450.00 $3.1M +14.4% —
May 5SEC Joy LiuGeneral Counsel Sell Plan 1,10420,729 held (−5%) $425.02 $469K +21.2% —
May 5SEC Sangeeta N. BhatiaDirector Sell Plan 3184,924 held (−6%) $423.73 $135K +21.5% —
Apr 3SEC Joy LiuGeneral Counsel Sell Plan 97821,833 held (−4%) $449.17 $439K +14.7% —
Mar 31SEC Carmen BozicEvp And Cmo Sell Plan 2,32933,076 held (−7%) $450.95 $1.1M +14.2% —
Mar 17SEC Carmen BozicEvp And Cmo Sell Plan 2,32935,405 held (−6%) $481.79 $1.1M +6.9% —
Mar 13SEC Duncan McKechnieEvp, Chief Commercial Officer Sell Plan 2,63312,489 held (−17%) $498.42 $1.3M +3.3% —
Mar 6SEC Duncan McKechnieEvp, Chief Commercial Officer Sell Plan 2,43715,122 held (−14%) $475.30 $1.2M +8.4% —
Mar 4SEC Joy LiuGeneral Counsel Sell Plan 89222,811 held (−4%) $495.96 $442K +3.8% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 15,580105,998 held (−13%) $495.38 $7.7M +4.0% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 5,995100,003 held (−6%) $496.16 $3.0M +3.8% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 3,498121,578 held (−3%) $494.33 $1.7M +4.2% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 3,278131,730 held (−2%) $488.27 $1.6M +5.5% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 2,725128,545 held (−2%) $490.54 $1.3M +5.0% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 2,520125,076 held (−2%) $493.29 $1.2M +4.4% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 2,510135,008 held (−2%) $487.13 $1.2M +5.7% —
Mar 3SEC Carmen BozicEvp And Cmo Sell Plan 2,32937,734 held (−6%) $480.31 $1.1M +7.2% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 1,72598,278 held (−2%) $496.95 $857K +3.6% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 949127,596 held (−1%) $491.30 $466K +4.8% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 460131,270 held (−0%) $489.32 $225K +5.3% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 400137,878 held (−0%) $479.75 $192K +7.4% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 240137,518 held (−0%) $482.84 $116K +6.7% —
Mar 3SEC Reshma KewalramaniCEO, President Sell Plan 120137,758 held (−0%) $481.50 $58K +7.0% —
Mar 2SEC Kristen AmbroseSvp & Chief Accounting Officer Sell Plan 3576,624 held (−5%) $483.36 $173K +6.5% —
Feb 26SEC Duncan McKechnieEvp, Chief Commercial Officer Sell Plan 2,50019,969 held (−11%) $486.35 $1.2M +5.9% —
Feb 26SEC Duncan McKechnieEvp, Chief Commercial Officer Sell Plan 2,41017,559 held (−12%) $489.00 $1.2M +5.3% —
Feb 26SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 1,84655,570 held (−3%) $486.35 $898K +5.9% —
Feb 26SEC Jonathan BillerGeneral Counsel Sell Plan 94513,659 held (−6%) $486.35 $460K +5.9% —
Feb 26SEC Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. Sell Plan 66818,432 held (−3%) $486.35 $325K +5.9% —
Feb 26SEC Mark E. BunnageEvp, Chief Scientific Officer Sell Plan 6207,284 held (−8%) $486.35 $302K +5.9% —
Feb 26SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 26046,763 held (−1%) $486.35 $126K +5.9% —
Feb 26SEC Kristen AmbroseSvp & Chief Accounting Officer Sell Plan 2236,981 held (−3%) $486.35 $108K +5.9% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 19,66282,124 held (−19%) $468.57 $9.2M +9.9% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 11,71263,171 held (−16%) $470.54 $5.5M +9.5% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 10,263101,786 held (−9%) $467.75 $4.8M +10.1% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 7,24174,883 held (−9%) $469.61 $3.4M +9.7% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 4,23758,934 held (−7%) $471.43 $2.0M +9.2% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 2,730113,897 held (−2%) $465.05 $1.3M +10.7% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 1,848112,049 held (−2%) $465.80 $861K +10.6% —
Feb 23SEC Amit SachdevEvp Chief Patient & Ext Af Off Sell Plan 920116,627 held (−1%) $463.91 $427K +11.0% —
Feb 19SEC Jonathan BillerGeneral Counsel Sell Plan 2,47616,992 held (−13%) $489.46 $1.2M +5.2% —
Feb 19SEC Mark E. BunnageEvp, Chief Scientific Officer Sell Plan 2,4379,668 held (−20%) $489.46 $1.2M +5.2% —
Feb 19SEC Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. Sell Plan 2,03121,544 held (−9%) $489.46 $994K +5.2% —
Feb 19SEC Kristen AmbroseSvp & Chief Accounting Officer Sell Plan 1,5578,388 held (−16%) $489.46 $762K +5.2% —
Feb 19SEC Jonathan BillerGeneral Counsel Sell Plan 1,24415,748 held (−7%) $473.68 $589K +8.7% —
Feb 19SEC Mark E. BunnageEvp, Chief Scientific Officer Sell Plan 1,1828,486 held (−12%) $473.68 $560K +8.7% —
Feb 19SEC Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. Sell Plan 81720,727 held (−4%) $473.68 $387K +8.7% —
Feb 19SEC Kristen AmbroseSvp & Chief Accounting Officer Sell Plan 6387,750 held (−8%) $473.68 $302K +8.7% —
Feb 19SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 60949,018 held (−1%) $489.46 $298K +5.2% —
Feb 19SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 36848,650 held (−1%) $473.68 $174K +8.7% —
Feb 18SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 1,50046,132 held (−3%) $499.99 $750K +3.0% —
Feb 18SEC Jonathan BillerGeneral Counsel Sell Plan 98816,838 held (−6%) $499.00 $493K +3.2% —
Feb 18SEC Sangeeta N. BhatiaDirector Sell Plan 2664,299 held (−6%) $500.00 $133K +3.0% —
Feb 12SEC Mark E. BunnageEvp, Chief Scientific Officer Sell Plan 2,02112,914 held (−14%) $460.43 $931K +11.9% —
Feb 12SEC Jonathan BillerGeneral Counsel Sell Plan 1,92520,819 held (−8%) $460.43 $886K +11.9% —
Feb 12SEC Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. Sell Plan 1,75122,046 held (−7%) $460.43 $806K +11.9% —
Feb 12SEC Kristen AmbroseSvp & Chief Accounting Officer Sell Plan 1,37610,127 held (−12%) $460.43 $634K +11.9% —
Feb 12SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 46651,436 held (−1%) $460.43 $215K +11.9% —
Jan 9SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 4,50042,293 held (−10%) $474.99 $2.1M +8.4% —
Jan 8SEC Charles F. Wagner Jr.Evp, Co & Fo Sell Plan 9,53237,725 held (−20%) $461.00 $4.4M +11.7% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 15,68136,456 held (−30%) $452.20 $7.1M +13.9% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 10,36026,096 held (−28%) $453.34 $4.7M +13.6% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 7,89967,298 held (−11%) $445.56 $3.5M +15.6% —
Dec 5SEC Charles F. Wagner Jr.Evp, Co & Fo Sell Plan 7,00037,725 held (−16%) $461.00 $3.2M +11.7% —
Dec 5SEC Charles F. Wagner Jr.Evp, Co & Fo Sell Plan 7,00044,725 held (−14%) $451.00 $3.2M +14.2% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 5,88057,946 held (−9%) $449.84 $2.6M +14.5% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 5,80952,137 held (−10%) $451.20 $2.6M +14.1% —
Dec 5SEC Ourania TatsisEvp, Chief Reg. & Quality Off. Sell Plan 4,50046,793 held (−9%) $449.99 $2.0M +14.5% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 4,46983,338 held (−5%) $440.40 $2.0M +16.9% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 4,35275,197 held (−5%) $444.36 $1.9M +15.9% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 2,46979,549 held (−3%) $443.21 $1.1M +16.2% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 2,32063,826 held (−4%) $448.78 $1.0M +14.8% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 2,07024,026 held (−8%) $455.22 $942K +13.1% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 1,32082,018 held (−2%) $441.26 $582K +16.7% —
Dec 5SEC Jeffrey M. LeidenChair Sell Plan 1,15266,146 held (−2%) $447.05 $515K +15.2% —
Dec 5SEC Jonathan BillerGeneral Counsel Sell Plan 34715,306 held (−2%) $449.00 $156K +14.7% —
Nov 19SEC Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. Sell Plan 2,50016,852 held (−13%) $434.58 $1.1M +18.5% —
Nov 17SEC Jeffrey M. LeidenChair Sell Plan 32,23445,396 held (−42%) $440.30 $14.2M +17.0% —
Nov 17SEC Jeffrey M. LeidenChair Sell Plan 21,33024,066 held (−47%) $441.35 $9.4M +16.7% —
Nov 17SEC Jeffrey M. LeidenChair Sell Plan 18,52825,186 held (−42%) $440.22 $8.2M +17.0% —
Nov 17SEC Jeffrey M. LeidenChair Sell Plan 1,16024,026 held (−5%) $441.05 $512K +16.8% —
Nov 17SEC Jeffrey M. LeidenChair Sell Plan 4024,026 held (−0%) $442.00 $18K +16.5% —
Oct 3SEC Jonathan BillerGeneral Counsel Sell Plan 69415,653 held (−4%) $404.21 $281K +27.4% —
Historical context

Similar past setups: not applicable. VRTX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with VRTX in the Research Lab

VRTX has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

VRTX closeInsider buyInsider sale
400450500550600DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-12EEarnings release filed 2026-05-04EEarnings release filed 2026-08-03EEarnings release filed 2026-11-02Sold $134,746 on 2026-05-04 · Sangeeta N. BhatiaSold $172,560 on 2026-02-26 · Kristen AmbroseSold $287,570 on 2026-06-26 · Carmen BozicSold $364,245 on 2026-06-01 · Joy LiuSold $416,244 on 2026-07-01 · Joy LiuSold $439,288 on 2026-04-01 · Joy LiuSold $442,396 on 2026-03-02 · Joy LiuSold $469,222 on 2026-05-01 · Joy LiuSold $471,413 on 2026-06-18 · Carmen BozicSold $628,935 on 2026-05-15 · Carmen Bozic, Mark E. BunnageSold $696,330 on 2026-11-16 · Nancy Thornberry, Sangeeta N. BhatiaSold $785,250 on 2026-06-05 · Carmen BozicSold $888,300 on 2026-05-29 · Carmen BozicSold $1,050,263 on 2026-03-27 · Carmen BozicSold $1,122,089 on 2026-03-13 · Carmen BozicSold $1,158,306 on 2026-03-04 · Duncan McKechnieSold $1,312,340 on 2026-03-11 · Duncan McKechnieSold $1,375,997 on 2026-02-13 · Jonathan Biller, Ourania Tatsis, Sangeeta N. BhatiaSold $1,587,264 on 2026-07-02 · Duncan McKechnie, Ourania TatsisSold $1,827,900 on 2026-06-15 · Carmen BozicSold $2,012,666 on 2026-02-18 · Edward Morrow Atkinson III, Jonathan Biller, Kristen Ambrose, Mark E. Bunnage, Ourania TatsisSold $2,137,455 on 2026-01-07 · Ourania TatsisSold $3,144,600 on 2026-05-12 · Carmen BozicSold $3,471,182 on 2026-02-11 · Edward Morrow Atkinson III, Jonathan Biller, Kristen Ambrose, Mark E. Bunnage, Ourania TatsisSold $4,394,252 on 2026-01-06 · Charles F. Wagner Jr.Sold $4,458,981 on 2026-02-17 · Edward Morrow Atkinson III, Jonathan Biller, Kristen Ambrose, Mark E. Bunnage, Ourania TatsisSold $4,613,094 on 2026-02-25 · Amit Sachdev, Duncan McKechnie, Edward Morrow Atkinson III, Jonathan Biller, Kristen Ambrose, Mark E. Bunnage, Ourania TatsisSold $6,307,135 on 2026-11-06 · Reshma KewalramaniSold $8,374,741 on 2026-11-12 · Charles F. Wagner Jr.Sold $20,857,497 on 2026-02-27 · Carmen Bozic, Reshma KewalramaniSold $27,479,583 on 2026-02-19 · Amit SachdevSold $37,215,095 on 2025-12-03 · Charles F. Wagner Jr., Jeffrey M. Leiden, Jonathan Biller, Ourania Tatsis
Bought, 12 months$0
Sold, 12 months$140M
Insiders buying0
Insiders selling14

Vertex Pharmaceuticals insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 14 sold $140M of VRTX stock on the open market; P/E 37.6 vs. a sector median of 24.5.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

VRTX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $70.9M sold (23 trades)Q4 2025Q1 2026: $76.1M sold (56 trades)Q1 2026Q2 2026: $9.4M sold (12 trades)Q2 2026Q3 2026: $2.0M sold (3 trades)Q3 2026Q4 2026: $15.4M sold (4 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$15.4M4
Q3 2026—0$2.0M3
Q2 2026—0$9.4M12
Q1 2026—0$76.1M56
Q4 2025—0$70.9M23

Valuation, profit and volume

P/E (trailing)37.6Sector median 24.5
Volume vs. 50-day1.1×Last 5 sessions

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Vertex Pharmaceuticals insiders reported open-market purchases totaling $0, while 14 insiders reported sales totaling $140M. 98 of 98 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

VRTX earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 2, 2026 +9.9% None -5.0%S&P -0.2% pending
Aug 3, 2026 -1.8% None +0.3%S&P +3.3% +16.6%
May 4, 2026 -2.7% Sold $469K +0.1%S&P +0.4% +4.1%
Feb 12, 2026 -2.7% Sold $3.5M +6.6%S&P -1.5% -4.5%
Nov 3, 2025 +4.2% None -0.9%S&P -1.0% +8.5%
Aug 4, 2025 -0.2% None -18.9%S&P +1.0% +5.9%
May 5, 2025 +2.5% None -10.2%S&P -1.4% -1.4%
Feb 10, 2025 +6.7% None -3.0%S&P +0.8% +10.5%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

VRTX short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-28: 64% of volume sold short2026-08-31: 69% of volume sold short2026-09-01: 59% of volume sold short2026-09-02: 56% of volume sold short2026-09-03: 69% of volume sold short2026-09-04: 62% of volume sold short2026-09-08: 64% of volume sold short2026-09-09: 54% of volume sold short2026-09-10: 61% of volume sold short2026-09-11: 63% of volume sold short2026-09-14: 68% of volume sold short2026-09-15: 68% of volume sold short2026-09-16: 63% of volume sold short2026-09-17: 65% of volume sold short2026-09-18: 63% of volume sold short2026-09-21: 61% of volume sold short2026-09-22: 57% of volume sold short2026-09-23: 64% of volume sold short2026-09-24: 73% of volume sold short2026-09-25: 74% of volume sold short2026-09-28: 63% of volume sold short2026-09-29: 72% of volume sold short2026-09-30: 61% of volume sold short2026-10-01: 65% of volume sold short2026-10-02: 58% of volume sold short2026-10-05: 59% of volume sold short2026-10-06: 60% of volume sold short2026-10-07: 55% of volume sold short2026-10-08: 43% of volume sold short2026-10-09: 31% of volume sold short2026-10-12: 37% of volume sold short2026-10-13: 59% of volume sold short2026-10-14: 40% of volume sold short2026-10-15: 30% of volume sold short2026-10-16: 40% of volume sold short2026-10-19: 29% of volume sold short2026-10-20: 29% of volume sold short2026-10-21: 51% of volume sold short2026-10-22: 65% of volume sold short2026-10-23: 58% of volume sold short2026-10-26: 55% of volume sold short2026-10-27: 49% of volume sold short2026-10-28: 67% of volume sold short2026-10-29: 61% of volume sold short2026-10-30: 72% of volume sold short2026-11-02: 70% of volume sold short2026-11-03: 60% of volume sold short2026-11-04: 58% of volume sold short2026-11-05: 63% of volume sold short2026-11-06: 53% of volume sold short2026-11-09: 47% of volume sold short2026-11-10: 54% of volume sold short2026-11-11: 44% of volume sold short2026-11-12: 60% of volume sold short2026-11-13: 45% of volume sold short2026-11-16: 45% of volume sold short2026-11-17: 42% of volume sold short2026-11-18: 57% of volume sold short2026-11-19: 42% of volume sold short2026-11-20: 48% of volume sold shortAug 28Sep 14Sep 28Oct 12Oct 26Nov 9
Latest (Nov 20): 48%20-day average: 58%Prior 2 months: 53%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded VRTX

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Thomas H TubervilleSenate Sold $1,001 - $15,000 May 3, 2024Aug 5, 2026 +28.4%
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +18.9%

Insiders at Vertex Pharmaceuticals

InsiderBoughtSoldLast filingPast buys beat S&PScore
Jeffrey M. LeidenChair — $60.9M Feb 26, 2026 — —
Amit SachdevEvp Chief Patient & Ext Af Off — $28.4M Jul 23, 2026 — —
Reshma KewalramaniCEO, President — $26.0M Nov 10, 2026 — —
Charles F. Wagner Jr.Evp, Co & Fo — $19.2M Nov 16, 2026 — —
Carmen BozicEvp And Cmo — $11.3M Jun 30, 2026 — —
Ourania TatsisEvp, Chief Reg. & Quality Off. — $6.5M Jul 23, 2026 — —
Duncan McKechnieEvp, Chief Commercial Officer — $5.7M Jul 7, 2026 — —
Jonathan BillerGeneral Counsel — $4.1M Feb 26, 2026 — —
Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. — $3.6M Feb 26, 2026 — —
Mark E. BunnageEvp, Chief Scientific Officer — $3.0M May 19, 2026 — —
Joy LiuGeneral Counsel — $2.1M Jul 6, 2026 — —
Kristen AmbroseSvp & Chief Accounting Officer — $2.0M Sep 1, 2026 — —
Nancy ThornberryDirector — $548K Nov 18, 2026 — —
Sangeeta N. BhatiaDirector — $416K Nov 18, 2026 — —
Daniel J. BrennanDirector — — Oct 22, 2026 — —
Grunsven Jasper VanEvp, Cp And Nppo — — Sep 10, 2026 — —
Bruce I. SachsDirector — — Aug 31, 2026 — —
Alan M. GarberDirector — — May 5, 2026 — —
Diana McKenzieDirector — — May 5, 2026 1 of 1 —
Jennifer SchneiderDirector — — May 5, 2026 — —
Suketu UpadhyayDirector — — May 5, 2026 — —
David AltshulerEvp, Chief Scientific Officer — — Jan 26, 2026 — —
Lloyd CarneyDirector — — Nov 20, 2025 — —

Board links: companies that share insiders with VRTX

Directors and executives who filed Form 4s for VRTX and another company in the last 12 months.

See the map →
  • DNLIDenali Therapeutics Nancy Thornberry Director here · Director at DNLI · latest filing Nov 18, 2026
  • GDYNGrid Dynamics Holdings Lloyd Carney Director here · Director at GDYN · latest filing Nov 9, 2026
  • INCYIncyte Suketu Upadhyay Director here · CFO at INCY · latest filing May 6, 2026
  • METMetLife Diana McKenzie Director here · Director at MET · latest filing Oct 5, 2026
  • ODTXOdyssey Therapeutics Jeffrey M. Leiden Chair here · Director at ODTX · latest filing May 11, 2026
  • VVisa Lloyd Carney Director here · Director at V · latest filing Nov 2, 2026
  • WATWaters Daniel J. Brennan Director here · Director at WAT · latest filing Oct 22, 2026
  • ZBHZimmer Biomet Suketu Upadhyay Director here · CFO at ZBH · latest filing May 5, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

VRTX stock: common questions

Are Vertex Pharmaceuticals insiders buying VRTX stock?

No. No Vertex Pharmaceuticals insider reported an open-market purchase of VRTX in the past 12 months.

Are Vertex Pharmaceuticals insiders selling VRTX stock?

14 insiders reported sales worth $140M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is VRTX's P/E ratio?

VRTX trades at about 37.6 times trailing earnings, compared with a median of 24.5 for the Health Care sector.

What is VRTX's 52-week range?

Over the past year VRTX has traded between $422.32 and $558.88. It last closed at $515.02 on Nov 20, 2026.